Biodel files fast-acting insulin formulation with FDA
This article was originally published in Scrip
Executive Summary
Biodel has filed its lead drug candidate VIAject, a fast-acting injected formulation of insulin for diabetes, with the US FDA. The company is seeking approval to market the injectable liquid in 10ml vials and in 3ml pen cartridges.